Sentence examples for depressed phase from inspiring English sources

Results from randomized, placebo-controlled trials support the use of quetiapine monotherapy and a combination of olanzapine fluoxetine in the depressed phase of bipolar disorder, while only limited data exists regarding the use of aripiprazole in this population.

New medication classes are needed to improve treatment effectiveness in the depressed phase of bipolar disorder (BD).

Diagnostically, 45 had MDD, three had BPAD I, and two had BPAD II, and were in the depressed phase.

The inclusion criteria for entry into the MBCT programme were that participants had to meet DSM IV criteria for MDD, Bipolar Affective Disorder (BPAD), Depressed phase, or Dysthymia.

In the accumbens area, medial thalamus and posterior cingulate cortex metabolism is abnormally elevated in the depressed phase of MDD and BD (Drevets et al. 2002a, 2004).

One study found that BD is associated with increased production of the pro-inflammatory cytokines, both in the manic and depressed phase (IL-8 and TNF-α) compared to healthy subjects [ 28].

Lithium is a mainstay of bipolar disorder treatment showing effectiveness in manic and depressed phases of the illness. 1 2 However, despite its effectiveness there are some disadvantages to its use including its narrow therapeutic range and adverse effects on the endocrine system.

Although similar G2/M-phase arrest and depressed S-phase were observed for the tumours in mice treated with both Pb-mAb (trastuzumab/HuIgG) and paclitaxel/ Pb-mAb (trastuzumab/HuIgG), tumours from mice given Pb-TCMC-HuIgG or paclitaxel/Pb-TCMC-HuIgG were beginning to exhibit recovery of the S-phase at 96 h.

Synchronisation in the G2/M-phase after 96 h, together with persistent reduced DNA synthesis and depressed S-phase, appears as the most prominent difference between targeted Pb-TCMC-trastuzumab and the nonspecific control, Pb-TCMC-HuIgG.

Concurrently, diminished levels of DNA synthesis and depressed S-phase were observed following the treatment regimen of paclitaxel/Pb-TCMC-trastuzumab, occurring at early time points and persisting throughout the 96-h study period.

For depression, the most robust laboratory finding is probably the HPA dysfunction of depressed patients during acute phase, which has led to the development of neuroendocrine challenge tests as putative biomarkers with potential application in clinical context [3].